Clopidogrel
Product Images NDC 54458-888

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 54458-888). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by International Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel Chemical Structure (Clopidogrel 1)

Chemical structure of Clopidogrel sulfate, showing the molecular arrangement including a thiophene ring, a bicyclic nitrogen-containing ring, a chlorine-substituted benzene ring, and a methyl ester functional group.*

FDA Label Image

Figure 8 (Clopidogrel 10)

A horizontal forest plot comparing the hazard ratios with 95% confidence intervals for Clopidogrel versus Aspirin across different qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral artery disease), and overall. The plot visually indicates which treatment favors Clopidogrel or Aspirin based on the hazard ratio values plotted along the x-axis.*

FDA Label Image

Eae (Clopidogrel 11)

Clopidogrel Tablets, USP 75 mg film-coated tablets packaging label shows product name, strength, and dosage form. The label includes instructions for opening the medication card, warnings to keep out of reach of children, tamper-evident details, and storage conditions. Packaged by International Laboratories and manufactured by Teva Pharmaceuticals, the label features Walmart branding and highlights package benefits like child resistance and recyclability. The package contains 30 tablets.*

FDA Label Image

Clopidogrel Tablets Usp 75 mg Bottle Label (Clopidogrel 12)

Clopidogrel Tablets USP 75 mg film-coated tablets packaged by International Laboratories, LLC. The label includes a barcode, dosage strength repeated multiple times, and an image of two pink, oval tablets imprinted with 'TV' on one side and '7314' on the other. The package contains 30 tablets. Additional information includes storage conditions, tamper-evident and child-resistant packaging warnings, and a pharmacist dispensing note.*

FDA Label Image

Figure 1 (Clopidogrel 2)

A horizontal bar chart labeled 'Effect on active metabolite AUC Mean and 90% confidence interval' showing the effect of various proton pump inhibitors (PPIs) coadministered with clopidogrel. The chart compares changes relative to clopidogrel administered alone for four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. Error bars indicate confidence intervals for each effect measurement.*

FDA Label Image

Figure 2 (Clopidogrel 3)

A cumulative event rate line graph comparing cardiovascular death, myocardial infarction, and stroke rates over a 12-month follow-up period between patients on Clopidogrel (+ aspirin) and placebo (+ aspirin). The graph shows lower cumulative event rates for Clopidogrel compared to placebo throughout the follow-up.*

FDA Label Image

Figure3 (Clopidogrel 4)

A forest plot chart showing the hazard ratio with 95% confidence intervals for various subgroups comparing Clopidogrel versus placebo. Subgroups include age groups, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction (MI), and previous stroke. The chart shows the number of participants and events in both Clopidogrel and placebo groups for each subgroup, with markers indicating the effect size favoring either Clopidogrel or placebo.*

FDA Label Image

Figure3_part2 (Clopidogrel 5)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups, including Heparin/LMWH use, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker use, and Ace inhibitor use, as well as overall results. The horizontal axis represents the hazard ratio values.*

FDA Label Image

Figure 4 (Clopidogrel 6)

A survival curve chart showing the percentage of deaths before first discharge over 28 days since randomization. The chart compares placebo and Clopidogrel, annotated with numbers and percentages of deaths for each group, including a noted 7% proportional risk reduction with Clopidogrel (p = 0.03).*

FDA Label Image

Figure 5 (Clopidogrel 7)

A line graph comparing the percentage of patients with death, re-infarction, or stroke before first discharge over days since randomization (up to 28 days) between Clopidogrel and placebo groups. The graph shows lower event rates for Clopidogrel (9.2%) versus placebo (10.1%), indicating a 9% proportional risk reduction with Clopidogrel.*

FDA Label Image

Figure 6 (Clopidogrel 8)

A data table presenting subgroup analyses of Clopidogrel versus placebo across categories such as gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. It compares numbers and percentages of events in each subgroup and includes a forest plot of odds ratios with 99% confidence intervals indicating effects favoring Clopidogrel or placebo.*

FDA Label Image

Figure 7 (Clopidogrel 9)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rate percent over 36 months of follow-up. Two lines represent event rates for aspirin and clopidogrel, with aspirin consistently higher. The graph includes a p-value of 0.045, indicating statistical comparison between the two treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.